EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

Promoter hypermethylation of SFRP1 as a prognostic and potentially predictive blood-based biomarker in patients with stage III or IV pancreatic ductal adenocarcinoma

Benjamin E Stubbe, Poul H Madsen, Anders C Larsen, Henrik B Krarup, Inge S Pedersen, Carsten P Hansen, Julia S Johansen, Stine D Henriksen, Ole Thorlacius-Ussing

Pancreatology · 2023-08 · 23 (5) · 512-521

DOI: 10.1016/j.pan.2023.05.003 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Pancreatology, 2023-08. Verfasst von Benjamin E Stubbe und 8 weiteren Autor:innen. Beteiligte Einrichtung: Department of Gastrointestinal Surgery, Aalborg University Hospital, Denmark; Clinical Cancer Research Center, Aalborg University Hospital, Aalborg, …. Hauptthemen laut MEDLINE: Pancreatic Neoplasms, Carcinoma, Pancreatic Ductal, Cell-Free Nucleic Acids. Die Arbeit wurde bisher 6-mal zitiert (Crossref) und nennt 41 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Svend Andersen Foundation.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

BACKGROUND: Pancreatic ductal adenocarcinoma remains one of the major causes of cancer-related mortality globally. Unfortunately, current prognostic biomarkers are limited, and no predictive biomarkers exist. This study examined promoter hypermethylation of secreted frizzled-related protein 1 (phSFRP1) in cfDNA as a prognostic biomarker and predictor of treatment effect in patients with metastatic FOLFIRINOX-treated PDAC and locally advanced PDAC. METHODS: We performed methylation-specific PCR of the SFRP1 genes' promoter region, based on bisulfite treatment. Survival was assessed as time-to-event data using the pseudo-observation method and analyzed with Kaplan-Meier curves and generalized linear regressions. RESULTS: The study included 52 patients with FOLFIRINOX-treated metastatic PDAC. Patients with unmethylated (um) SFRP1 (n = 29) had a longer median overall survival (15.7 months) than those with phSFRP1 (6.8 months). In crude regression, phSFRP1 was associated with an increased risk of death of 36.9% (95% CI 12.0%-61.7%) and 19.8% (95% CI 1.9-37.6) at 12 and 24-months, respectively. In supplementary regression analysis, interaction terms between SFRP1 methylation status and treatment were significant, indicating reduced benefit of chemotherapy. Forty-four patients with locally advanced PDAC were included. phSFRP1 was associated with an increased risk of death at 24-months CONCLUSIONS: This indicates that phSFRP1 is a clinically useful prognostic biomarker in metastatic PDAC and possibly in locally advanced PDAC. Together with existing literature, results could indicate the value of cfDNA-measured phSFRP1 as a predictive biomarker of standard palliative chemotherapy in patients with metastatic PDAC. This could facilitate personalized treatment of patients with metastatic PDAC.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Pancreatic NeoplasmsCarcinoma, Pancreatic DuctalCell-Free Nucleic AcidsHumansPrognosisAntineoplastic Combined Chemotherapy ProtocolsBiomarkers, TumorPromoter Regions, GeneticMembrane ProteinsIntercellular Signaling Peptides and ProteinsSecreted Frizzled-Related Proteins

Stichwörter der Autor:innen

BiomarkerBlood-basedDNA methylationPancreatic ductal adenocarcinomaSurvival

Substanzen

Biomarkers, TumorCell-Free Nucleic AcidsMembrane ProteinsIntercellular Signaling Peptides and ProteinsSFRP1 protein, humanSecreted Frizzled-Related Proteins

Autor:innen und Institutionen

  • Department of Gastrointestinal Surgery, Aalborg University Hospital, Denmark; Clinical Cancer Research Center, Aalborg University Hospital, Aalborg, Denmark; Department of Clinical Medicine, Aalborg University, Denmark.…
  • Clinical Cancer Research Center, Aalborg University Hospital, Aalborg, Denmark; Department of Molecular Diagnostics, Aalborg University Hospital, Denmark.
  • Department of Gastrointestinal Surgery, Aalborg University Hospital, Denmark; Clinical Cancer Research Center, Aalborg University Hospital, Aalborg, Denmark; Department of Clinical Medicine, Aalborg University, Denmark.
  • Clinical Cancer Research Center, Aalborg University Hospital, Aalborg, Denmark; Department of Molecular Diagnostics, Aalborg University Hospital, Denmark; Department of Clinical Medicine, Aalborg University, Denmark.
  • Department of Surgery, Copenhagen University Hospital - Rigshospitalet, Copenhagen, Denmark.
  • Department of Medicine, Copenhagen University Hospital - Herlev and Gentofte, Herlev, Denmark; Department of Clinical Medicine, Faculty of Health and Medical Sciences, University of Copenhagen, Copenhagen, Denmark; Depa…

Förderung

  • Svend Andersen Foundation

Zitieren

APA

Stubbe, B. E., Madsen, P. H., Larsen, A. C., Krarup, H. B., Pedersen, I. S., Hansen, C. P., Johansen, J. S., Henriksen, S. D., & Thorlacius-Ussing, O. (2023). Promoter hypermethylation of SFRP1 as a prognostic and potentially predictive blood-based biomarker in patients with stage III or IV pancreatic ductal adenocarcinoma. Pancreatology, 23(5), 512-521. https://doi.org/10.1016/j.pan.2023.05.003

Vancouver

Stubbe BE, Madsen PH, Larsen AC, Krarup HB, Pedersen IS, Hansen CP, et al. Promoter hypermethylation of SFRP1 as a prognostic and potentially predictive blood-based biomarker in patients with stage III or IV pancreatic ductal adenocarcinoma. Pancreatology. 2023;23(5):512-521. doi:10.1016/j.pan.2023.05.003

BibTeX
@article{Stubbe2023,
  author = {Stubbe, Benjamin E and Madsen, Poul H and Larsen, Anders C and Krarup, Henrik B and Pedersen, Inge S and Hansen, Carsten P and Johansen, Julia S and Henriksen, Stine D and Thorlacius-Ussing, Ole},
  title = {Promoter hypermethylation of SFRP1 as a prognostic and potentially predictive blood-based biomarker in patients with stage III or IV pancreatic ductal adenocarcinoma},
  journal = {Pancreatology},
  year = {2023},
  volume = {23},
  number = {5},
  pages = {512--521},
  doi = {10.1016/j.pan.2023.05.003}
}
Kostenlos starten →